phosphoproteomics | GenomeWeb

phosphoproteomics

Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.

The scientists used their method, called PS-ChAP, to gain insight into cellular phosphorylation signaling pathways in chromatin down to the gene level.

The company is developing multiplexed and reverse-phase array versions of its protein phosphorylation-detection technology.

NEW YORK (GenomeWeb News) – The National Cancer Institute today said that it has released a dataset of proteins and phosphopeptides identified by researchers using deep proteomic and phosphoproteomic methods to analyze breast cancer samples.

NEW YORK (GenomeWeb News) – Activiomics announced recently a research deal with Kyowa Hakko Kirin for use of Activiomics' mass spectrometry-based technology to "elucidate signaling mechanism of lead compounds in relevant cell-based systems."

As part of the deal, Kinaxo will use its PhosphoScout phosphoproteomics technology to assess drugs under development at Takeda.

The UK firm will use the investment to further build partnerships with pharmaceutical and biotech firms and identify novel biomarkers.

Under the technology agreement Activiomics will use its mass spectrometry-based TIQUAS platform to gain insight into the signaling mechanisms of therapeutic antibodies in relevant cell-based systems.

Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.

The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.